Amarin Corp Plc (AMRN)

[couldbebetter]

$24 (Note this is assigning zero value to the US market as the sales reps
make it more a liability than an asset unless a way is found to
counter generics effectively.) Should the generics be countered
and IF a BP properly promotes and distributes Vascepa with an
established sales force, then it would have solid value, for
which I would hope we would get a CVR.